I-MAB
IMAB
Company Profile
Business description
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People’s Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
Contact
2440 Research Boulevard
Suite 400
RockvilleMD20850
USAT: +1 240 745-6330
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
220
I-MAB News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,687.60 | 54.50 | 0.63% |
CAC 40 | 7,255.01 | 41.69 | 0.58% |
DAX 40 | 19,322.59 | 176.42 | 0.92% |
Dow JONES (US) | 44,296.51 | 426.16 | 0.97% |
FTSE 100 | 8,262.08 | 112.81 | 1.38% |
HKSE | 19,287.22 | 57.25 | 0.30% |
NASDAQ | 19,003.65 | 31.23 | 0.16% |
Nikkei 225 | 38,941.87 | 658.02 | 1.72% |
NZX 50 Index | 13,128.16 | 86.26 | 0.66% |
S&P 500 | 5,969.34 | 20.63 | 0.35% |
S&P/ASX 200 | 8,443.60 | 49.80 | 0.59% |
SSE Composite Index | 3,274.91 | 7.72 | 0.24% |